Grifols S.A. - ADR

The total asset value of Grifols SA - ADR stood at 0 as on 30-Sep-24

The share price of Grifols SA - ADR is $7.15 (NASDAQ) as of 17-Apr-2025 15:43 EDT. Grifols SA - ADR has given a return of -12.74% in the last 3 years.

Grifols SA - ADR has a market capitalisation of $ 5,814 Mln as on 16-Apr-2025. As per Value Research classification, it is a company.

The P/B ratio of Grifols SA - ADR is 0.71 times as on 16-Apr-2025, a 86% discount to its peers’ median range of 5.17 times.

The P/E ratio of Grifols SA - ADR is 26.88 times as on 16-Apr-2025, a 31% discount to its peers’ median range of 39.11 times.

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Grifols SA - ADR and enter the required number of quantities and click on buy to purchase the shares of Grifols SA - ADR.

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factor VIII/von Willebrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It also markets diagnostic testing equipment, reagents, and other equipment; offers biological products and manufacturing services; and manufactures and sells plasma to third parties. In addition, the company offers Yimmugo IDP, an immunology drug; Yimmugo PTI, a hematology drug; and Prolastin vials, a pulmonology drug. Further, it develops Xembify Pre-filled syringes, Gamunex Bags, and FlexBag; Xembify Biweekly dosing, Fibrinogen, and VISTASEAL; Prolastin-C AADT and Fostamatinib; Xembify " CLL, Albumina 20% and 5%, and Trimodulin; Alfa-1 AT 15%, GRF6019, GRF6021, Aßvac402, AKST4290, and AKST4290; GIGA 2339 and GIGA564; and recIG, Alfa-1 AT - in non-cystic fibrosis bronchiectasis, and OSIG that are in pre-clinical stage. It has collaboration agreements with Canadian Blood Services to supply grains of Immunoglobulin. The company was founded in 1909 and is headquartered in Barcelona, Spain. Address: Avinguda de la Generalitat 152-158, Barcelona, Spain, 08174

The CEO & director of Mr. Thomas H. Glanzmann. is Grifols SA - ADR, and CFO & Sr. VP is Mr. Thomas H. Glanzmann.

There is no promoter pledging in Grifols SA - ADR.

Some of the close peers are:

No, TTM profit after tax of Grifols SA - ADR was $0 Mln.